Materials‐Guided Gene‐Ionizable Lipid Nanoparticles to Reverse Iron‐Associated Immune Resistance in Renal Cancer
Advanced Science · 2026
DOI: 10.1002/advs.202600078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xin Jin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Kidney Neoplasms, Nanoparticles, Carcinoma, Renal Cell, Iron. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese National Natural Science Foundation, Hunan Provincial Natural Science Foundation for Young Scholars (Class A) Continuation, Science and Technology Innovation Program of Hunan Province.
Abstract (Originalsprache)
Iron overload is a common metabolic disturbance in cancer and contributes to poor outcomes in renal cell carcinoma (RCC), yet its effects on the tumour immune microenvironment remain unclear. Here we identify a previously unrecognized immunosuppressive axis in which iron overload downregulates the palmitoyltransferase ZDHHC12 in CD8 + T cells, leading to impaired palmitoylation of the mitochondrial protein FDX1. This stabilizes FDX1 and drives cuproptosis, a recently described copper‐dependent cell death pathway, thereby compromising T cell effector function and diminishing responses to immune checkpoint blockade. To restore T cell activity, we engineered lipid nanoparticles (ZDHHC12‐LNPs) for the delivery of Zdhhc12. These nanoparticles exhibited optimal physicochemical properties, efficiently restored FDX1 palmitoylation, rescued CD8 + T cell function, and synergized with PD‐1 blockade in preclinical RCC models without inducing systemic toxicity. Our findings uncover the iron‐ZDHHC12‐FDX1 axis as a metabolic checkpoint of T cell immunity and demonstrate a nanotechnology‐based strategy to overcome iron‐driven immunosuppression, offering translational potential for patients with iron‐overloaded RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Uro-Oncology Institute of Central South University, Changsha, Hunan, China.
- Department of Biomedical Engineeringfaculty of Engineering, University Malaya, Kuala Lumpur, Malaysia.
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
- Robotic Minimally Invasive Surgery Center, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Urology, Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: João Conde
Förderung
- Chinese National Natural Science Foundation
- Hunan Provincial Natural Science Foundation for Young Scholars (Class A) Continuation
- Science and Technology Innovation Program of Hunan Province
Zitieren
APA
Jin, X., Hong, Y., Yin, C., Guo, W., Wang, Y., Zeng, R., Liu, R., Ding, Z., Liu, X., Ren, S., Liang, Q., Wang, Y., Zhang, X., Conde, J., Li, Y., Ma, X., & Gu, L. (2026). Materials‐Guided Gene‐Ionizable Lipid Nanoparticles to Reverse Iron‐Associated Immune Resistance in Renal Cancer. Advanced Science. https://doi.org/10.1002/advs.202600078
Vancouver
Jin X, Hong Y, Yin C, Guo W, Wang Y, Zeng R, et al. Materials‐Guided Gene‐Ionizable Lipid Nanoparticles to Reverse Iron‐Associated Immune Resistance in Renal Cancer. Advanced Science. 2026. doi:10.1002/advs.202600078
BibTeX
@article{Jin2026,
author = {Jin, Xin and Hong, Yulong and Yin, Chengliang and Guo, Wanyang and Wang, Yaxuan and Zeng, Ruijiang and Liu, Ruilin and Ding, Zexian and Liu, Xinlin and Ren, Shangqing and Liang, Qiyang and Wang, Yaohui and Zhang, Xu and Conde, João and Li, Yuan and Ma, Xin and Gu, Liangyou},
title = {Materials‐Guided Gene‐Ionizable Lipid Nanoparticles to Reverse Iron‐Associated Immune Resistance in Renal Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202600078}
}
EUVIMED